Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of IPI-504 plus trastuzumab in pretreated HER2-positive advanced or metastatic breast cancer
2009-010435-40Phase 2Terminated
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retaspimycin and trastuzumab in breast cancer, sponsored by Infinity Pharmaceuticals, Inc. Primary endpoints: Overall response rate, Safety and 1 more. Started Apr 2009; status: terminated.
02
Drugs
retaspimycintrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-010435-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010435-40.